Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01635998 · ClinicalTrials.gov registry record · NA

Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation

A NA study of Atrial Fibrillation and Uncontrolled Hypertension, sponsored by Vivek Reddy.

Completed
Registry status
NA
Development phase
50
Enrollment target
8
Study locations

NCT01635998: Completed NA study of Atrial Fibrillation and Uncontrolled Hypertension, sponsored by Vivek Reddy.

NCT01635998 is a NA study of Atrial Fibrillation and Uncontrolled Hypertension that has completed, run by Vivek Reddy. The registered enrollment target is 50 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01635998, a NA study of Atrial Fibrillation and Uncontrolled Hypertension, has completed, sponsored by Vivek Reddy.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
8
Study locations

Study Summary

The objective of the H-FIB trial is to determine the role of renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.

Primary Outcome

The primary endpoint of this study is anti-arrhythmic drug (AAD)-free single-procedure freedom from AF recurrence through 12 months (not including a 90 day blanking period).

Interventions

  • DEVICE Boston Scientific Vessix Renal Denervation System

Study Locations (8)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Women's Hospital - Boston

Other

  • Na Homolce Hospital - Prague
  • Siberian Biomedical Research Center Ministry of Health Russian Federation - Novosibirsk

California

  • Regional Cardiology Associates - Sacramento

Kansas

  • University of Kansas Medical Center - Kansas City

New York

  • Mount Sinai Hospital - New York

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2012-09-17
Est. Completion 2019-07-11
Phase NA
Vivek Reddy

20 total trials

What the finished NCT01635998 record still lists

NCT01635998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Boston Scientific Vessix Renal Denervation System is the first listed.

NCT01635998 lists 8 locations in 6 states (Massachusetts, Other, California).

Frequently Asked Questions

What is clinical trial NCT01635998 about?

NCT01635998 is a clinical study titled "Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation". The objective of the H-FIB trial is to determine the role of renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (us...

What is the current status of trial NCT01635998?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2012-09-17. Estimated completion is 2019-07-11.

What conditions does trial NCT01635998 study?

This clinical trial studies the following conditions: Atrial Fibrillation, Uncontrolled Hypertension.

What interventions are being tested in trial NCT01635998?

The interventions under investigation include: Boston Scientific Vessix Renal Denervation System (DEVICE).

Who is sponsoring clinical trial NCT01635998?

This trial is sponsored by Vivek Reddy, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01635998 being conducted?

This trial has 8 study locations across California, Kansas, Massachusetts, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01635998's enrollment target sits among peer trials

50 174th of 202 higher than 25 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01635998, the US trial registry maintained by the National Library of Medicine. NCT01635998 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.